Compare GRF & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GRF | INCR |
|---|---|---|
| Founded | 1989 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 47.4M |
| IPO Year | N/A | 2021 |
| Metric | GRF | INCR |
|---|---|---|
| Price | $9.97 | $1.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.8K | ★ 36.9K |
| Earning Date | 01-01-0001 | 05-01-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $69.54 |
| Revenue Next Year | N/A | $41.75 |
| P/E Ratio | $8.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.50 | $0.68 |
| 52 Week High | $11.85 | $1.77 |
| Indicator | GRF | INCR |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 62.01 |
| Support Level | $9.96 | $0.84 |
| Resistance Level | $10.13 | $1.23 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 29.33 | 74.20 |
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.